Friday, February 28, 2020

Lupine Publishers| New Clinical Initiatives at the Steno Diabetes Center Odense and in the Region of Southern Denmark

Abstract

In general, patients with diabetes still have an increased mortality risk, increased risk of micro- and macro-vascular complications and a decreased quality of life. Despite better options for treatment and care, to many diabetes patients are still not in optimized treatment control in order to avoid complications. In Denmark there is a long tradition for focused diabetes treatment and care, as well as research and manufacturing insulin and other antihyperglycemic drugs. Five Steno Diabetes Centers, one in each region of Denmark, have emerged as a part of the Danish Health Care System. The overall aim for these centers is to provide optimized treatment and care for all patients with diabetes regardless of age, type of diabetes, co-morbidity and where in the Health Care System the patient is treated. The vision is to provide treatment, research and education at the highest international level in the future. Steno Diabetes Center Odense is a new diabetes center which will attempt to realize this aim and vision for patients with diabetes and health care professionals in the Region of Southern Denmark. In this paper we describe the present and forthcoming new clinical initiatives at Steno Diabetes Center Odense and at its partner hospitals in the Region of Southern Denmark, which is planned or in the process of implementation.

Introduction

The Danish physician Hans Christian Hagedorn (1888-1971) initiated the industrial production of insulin in Denmark in 1923 together with the Danish physiologist August Krogh (1874-1949) by founding the company Nordisk Insulin Laboratorium, which much later merged into the pharmaceutical company Novo Nordisk A/S [1]. Further in 1936, Hans Christian Hagedorn co-discovered the principle of addition of protamine to insulin, in order to protract its time of action [2]. This principle has been marketed and in use since 1946, known as Neutral Protamine Hagedorn insulin (NPH insulin). The initial idea of Nordisk Insulin Laboratorium was to ensure the availability of insulin for the patients, and to support research, treatment and care of patients with diabetes. Thus, Hans Christian Hagedorn founded Steno Memorial Hospital in 1932, a private-based hospital solely for treatment and care of patients with diabetes. In 2017, Steno Memorial Hospital, now called Steno Diabetes Center Copenhagen, was entrusted from Novo Nordisk A/S to the National Danish Health Care System, for future treatment and care of patients with diabetes in the Capital Region of Denmark. At the same time, the Novo Nordisk Foundation granted a donation of approximately 1 billion euros to support the foundation and development of similar Steno Diabetes Centers in the other four regions of Denmark, thus covering the entire Denmark with specialized centers within prevention, treatment, care and research in diabetes. During 2018, four diabetes centers have been formed: Steno Diabetes Center Odense (SDCO), Steno Diabetes Center Århus (SDCA), Steno Diabetes Center of Northern Jutland (SDCN) and Steno Diabetes Center Zeeland (SDCS)(Figure 1). All centers are attached to general hospitals in which most other specialties are present. The grant from the Novo Nordisk Foundation also covers new buildings, which will be built and specially designed to future management of diabetes care and treatment, comprising treatment of both children and adults, in addition to diabetes research and education of health care professionals.
Figure 1:
lupinepublishers-openaccess-journal-diabetes-obesity

Steno Diabetes Center Odense

SDCO was founded January 1st, 2018 and is currently taking care of approximately 3200 patients with all kinds of diabetes. The four core activities of SDCO are: prevention and treatment of diabetic complications, clinical research, education of health care professionals and cross-sectorial collaboration between the different health care sectors. The overall aim is to provide the highest international level of treatment, care and research within diabetes, in order to give patients with diabetes in the future a lifespan and quality of life not different from the population without diabetes. SDCO will have the overall responsibility for the quality and treatment and care of patients with diabetes for the whole diabetes population of the Region of Southern Denmark, which is currently approximately 56.000 patients with diabetes [3], regardless of where the individual patient is treated (hospitals, outpatient clinics, primary health care providers etc).
To obtain the goal of ensuing and increasing the quality of patient care and treatment a close collaboration between SDCO, SDCO partner hospitals, communities and primary health care providers has to be reinforced and further developed (Figure 2). In addition to current standard treatment of patients with diabetes, numerous additional new clinical and non-clinical activities and projects will be developed and implemented within the next ten years. The standard care and treatment activities will be continued within the Regional budget, whereas the new additional activities will be covered within the grant from the Novo Nordisk Foundation.
Figure 2:
lupinepublishers-openaccess-journal-diabetes-obesity

Steno Diabetes Center Odense

The aim of the new clinical initiatives is to add on to the current standard management of patient care and treatment at the center and its partner hospitals, and thus to improve the overall quality of patient care and treatment for all patients with diabetes in the future in the Region of Southern Denmark.

Definition of a Clinical Initiative

The new initiatives as defined in the screenplay for SDCO is a time-limited project described in detail in a specific project description, which has to be approved in advance by the board of SDCO. Thus, the initiative runs into different phases: preparation of synopsis-approval by the board-preparation of detailed project description-approval by the board-detailed planning-initiation and implementation in the clinic-completion of the project-evaluationfinal decision to continue or not as standard care. Overall the project continues for three years. Based on evaluation of key parameters it is decided whether the initiative will continue as future standard management in the clinic or not.

Approved Clinical Initiatives at SDCO Under or Awaiting Implementation

Adults with Diabetes: Table 1 gives an overview of the various clinical initiatives which have been planned, approved and initiated from 2018 until the present date at SDCO and, for some initiatives, at the partner hospitals in the Region of Southern Denmark.
Table 1: New approved clinical initiatives from the Steno Diabetes Center Odense for patients with diabetes from 2018-19 and status of implementation in the clinic.
lupinepublishers-openaccess-journal-diabetes-obesity
Extended Opening Hours: The extended opening hours late afternoon every week gives patients with full-time work the possibility to have appointments in the clinic outside their working hours. In this initiative there is also an option to have acute appointments at the out-patient clinic according to the need. Thus, patients with dysregulated diabetes or newly diagnosed patients without ketoacidosis admitted to the emergency ward, do have the option to have an appointment the following day at SDCO.
Diabetes Psychologist: The American Diabetes Association guidelines for the management of diabetes [4] recommend that psycho-social support should be an integrated part of diabetes care and should be offered. Some evidence support this notion, and that psychologic intervention can result in increased acceptance of the disease, optimized self-management and a reduced number of psychological barriers towards better disease control [5-7]. In this initiative, the psychology team will provide support to the other health care professionals at SDCO and its partner hospitals to improve their understanding and management of patients with psychologic challenges in relation to their diabetes. Further, to provide individual psychologic intervention to patients with psychologic problems and challenges in relation to their diabetes, and finally develop this psychologic program to patients.
Screening for Diabetic Complications Package: The screening for diabetic complications is traditionally offered on different appointments and by different specialists on different days. In this initiative screening for all complications is done at the same day in one location. Thus, the patient meets in the out-patient clinic at SDCO and have blood and urine samples taken, ECG (patients older than 65 years). Thereafter, the patient goes to the optometrist to have a fundus-photo and an optical coherence tomography taken. The pictures will be send to an ophthalmologist for immediate evaluation and description. The patient goes to the podiatrist to have a foot examination, counseling and risk evaluation. Finally the patient is seen by the endocrinologist, who takes care of collection and evaluation of all results, give advice, change or optimize the pharmacologic treatment if needed, and plan for future treatment and visits. The whole screening package takes approximately 2½ hours for the patient.
Screening and Treatment of Diabetic Autonomous Neuropathy: The prevalence and incidence of diabetic complication varies and is reduced by improving glycemic control in both type 1 and type 2 diabetes [8,9]. Autonomous neuropathy is related to the diabetes duration. In this initiative, patients with neuropathy and suspected gastroparesis is referred to a thorough and structured workup involving both the endocrinologist and gastroenterologist, and including both endoscopy and ventricular motility tests, before eventually treatment.
Screening and Treatment of Patients with Concomitant Renal Insufficiency: Patients with diabetes complicated with diabetic kidney disease have an increased morbidity and mortality. Optimal treatment of this group of patients seems to require a team-based management approach [10]. Evidence suggests that multidisciplinary consultations with an endocrinologist, nephrologist and diabetes nurse together may improve renal outcomes in these patients [11] and that increased focus on multifactorial intervention improves long-term renal outcomes [12]. In the future multidisciplinary out-patient clinic at SDCO, patients with an estimated glomerular filtration rate (eGFR) less than 30 ml/min, or between 30 and 40 ml/min and concomitant complications like acidosis, anemia, hypertension or calciumphosphate problems, will be referred to this team. Patients with progressive proteinuria will also have this opportunity.
Courses for Patients with Recurrent Ketoacidosis or Severe Hypoglycemia: Hypoglycemia is associated with an increased risk of hospital admission, falls and accidents in patients with diabetes. It can have significant physical and mental consequences and is the most important limiting factor in yielding and maintaining good glycemic control in patients with type 1 diabetes [13]. New technology such as continuous glucose monitoring systems (CGM) can have a significant effect of reducing severe hypoglycemia in patients, in particular patients with hypoglycemia unawareness. It seems that by combining CGM by focused and structured patient education do have the best outcome in minimizing the risk of severe hypoglycemia in patients with type 1 diabetes and hypoglycemia unawareness [14]. A multidisciplinary group-based patient education program with a diabetes nurse, endocrinologist, psychologist and dietician will educate and empower the patient to improve skills in order to prevent and avoid future severe hypoglycemic events. The family of the patient is included in this program, and the sessions will focus on: theory, fear of hypoglycemia, coping of unawareness, insulin adjustments, physical activity, carbohydrates and glucose sensors. These sessions can be combined with individual counseling.
Diabetes Screening and Assistance from Diabetes Team in Other Departments: Many patients admitted to the hospital for other somatic reasons such as cardiovascular disease, surgery, neurological disease and infectious diseases also have diabetes, particularly type 2 diabetes. Specialists and nurses at these departments do not always have the necessary skills and focus on care and treatment of patients with diabetes. Studies have shown that implementation of a specialized team of diabetes nurses supervised by an endocrinologist providing assistance to other departments at the hospital, can have a positive impact in reducing the length of hospitalization stay, and an increased satisfaction for both patient and health care professionals at the department [15- 17]. The aim of the initiative at SDCO is three-fold: optimization of care and treatment for all patients with diabetes admitted to the hospitals regardless of the department, a systematic opportunistic screening of patients with unknown diabetes by HbA1c, and to develop and improve the skills and competences in diabetes management of the health care professionals at all departments of the hospital. Thus, in all departments where an opportunistic screening for diabetes is considered relevant based on the characteristics of the population, all patients will at the time of admittance have a blood sample taken to be analyzed for HbA1c. In patients with unknown diabetes who have an increased HbA1c ≥ 48 mmol/mol, will have this re-tested and if confirmed, the specialized diabetes team will be involved to evaluate and manage the patient. The diabetes nurse will provide assistance to all patients with known diabetes where the department requests assistance and help in diabetes management. The team from SDCO will provide continuous training and regular theme-based courses for the health care professionals at these departments.
As an add-on to the above described initiative, a project including a clinical pharmacist intervention is considered. Recent studies suggest that a pharmacist-driven medication review, patient interview and follow-up in patients admitted to the acute admission ward may reduce the rate of readmissions and emergency department visits in these patients [18]. The proposed project is to include a clinical pharmacist to intervene in all in-patients who have significant pharmacologic treatment changes during the hospital admission. The intervention will include a medication review and evaluation, a patient motivational interview and follow-up with the primary health care sector after discharge from hospital.
Diabetes Screening and Assistance from Diabetes Team in Psychiatric Departments: The patients with diabetes and psychiatric co-morbidities constitute a particular challenge. Psychiatric patients have a two- to four-fold increased prevalence of diabetes and the metabolic syndrome compared to the general population. Patients with severe psychiatric diseases and diabetes have a significant increased mortality [19]. As previously described studies of admitted patients with somatic disease support the impact of a specialized diabetes team providing assistance to departments [15-17]. In this initiative, a specialized nurse-based diabetes team will provide assistance to health care professionals at the psychiatric departments and in the regional out-patient psychiatric clinics, in the management and care of patients with diabetes. As for the non-psychiatric departments, the team from SDCO will provide continuous training and regular theme-based courses for the health care professionals at the psychiatric departments. The diabetes nurse in this initiative will be supervised by an endocrinologist.
Advice before Pregnancy: Fertile women with diabetes have an increased risk of giving birth to a child with malformations and pregnancy complications if their glycemic control is not optimized before conception. Optimized glycemic control before and during pregnancy reduces the risk for diabetic complications, severe hypoglycemia, preterm delivery, macrosomia and malformations and neonatal hypoglycemia. In this initiative women with a wish of pregnancy in the near future and having either type 1 or type 2 diabetes and ethnicity other than Danish are offered a program with multidisciplinary advice covering adjustment of medicine, co-morbidity, goal of treatment, injection technique, blood glucose measurement, carbohydrate counting, vitamin supplements and complication screening. This program will be provided by the endocrinologist, diabetes nurse and dietician. In addition the women are offered a group-based program covering planning of pregnancy and follow-up during and after pregnancy.
Start-Up Course for Patients with Newly Diagnosed Type 1 Diabetes: For patients with type 1 diabetes previous studies show that intensively treated patients have a significant better long-term outcome with a reduced incidence of microvascular complications [9] and cardiovascular disease [20]. Many barriers towards optimized glycemic control can be identified such as risk and fear for hypoglycemia, insufficient knowledge of long-term consequences of the disease, acceptance problems and social challenges. Thus, it is of decisive importance that management of the patient with newly diagnosed type 1 diabetes is well-structured, thorough and individualized. At SDCO newly diagnosed type 1 diabetes patients will be followed in a 6 months ‘start-up package’ which will comprise a multidisciplinary team course and patient interviews, individualized and group-based, covering all elements of treatment, self-management and social significance for the patient and their relatives. The structured course will be supplemented by videos and e-learning to support empowerment and ‘living the good life with diabetes’ in these patients.

Preparation before Surgery

Patients with diabetes who are planned for surgery may have an increased risk of complications during or after surgery. Studies have shown that the risk of deep infections postoperatively is increased in patients with a high level of HbA1c [21], an increased risk of infections, infarctions and reduced survival is linked to perioperative hyperglycemia [22], and patients with an HbA1c above 70 mmol/mol who underwent cardiovascular surgery was found to have up to a four-fold risk of mortality [23]. A recent study found that initiating and optimizing basal insulin therapy in patients planned for cardiac surgery resulted in fewer infections postoperatively and a shorter hospitalization stay [24]. In this initiative, type 1 and type 2 diabetes patients treated with insulin are offered referral to SDCO for evaluation and optimization of insulin treatment before planned surgery. The patient will be evaluated by an endocrinologist, diabetes nurse and dietician at SDCO. Focus for evaluation, treatment and advice will be to: optimize insulin therapy and antihypertensive treatment if needed, patient advice regarding precautions related to diabetes management perioperatively, and an individualized diet plan if needed. Patients planned for orthopedic and gastrointestinal surgery will be included in this initiative.

Children and Adolescents with Diabetes

As listed in Table 1, the approved initiatives for children and adolescents with type 1 diabetes resembles those planned for adult patients with diabetes as previously described. The education programs, theme-based meetings and start-up courses will be adapted to the age-group (pre-school age, school-age below 15 years and school-age above 15 years) and adjusted to the special needs and challenges in these patients. The initiative concerning a diabetes psychologist will be distinctively different from the initiative for adults. Thus, it will comprise of systematic screening and evalulation of children and adolescents with diabetes, groupbased therapy if needed, intervention using the acceptance and commitment therapy (ACT) method, psycho-education sessions for patients and their families, and training and supervision to the health care professionals.
Planned Initiatives in Near Future at SDCO Awaiting Approval: The future initiatives in pipeline are listed on Table 2. The initiatives will cover both clinical and non-clinical initiatives and for both adults, children and adolescents with various forms of diabetes. The non-clinical initiatives are meant to support future management and treatment of patients, including the new clinical initiatives. Thus, a unit for the evaluation of new technology, research and development will guide the use of new technology to the right patients in order to benefit most patients taken costbenefit analyses into consideration as well. A unit for quality and follow-up will provide surveillance of key quality indicators of the patients treated at SDCO and of patients treated elsewhere in the Region of Southern Denmark, and will improve quality of patient management by providing data on the patient population and at the individual level. A mutual model for the evaluation of the above initiatives will be developed and described.
Table 2: Planned future clinical and non-clinical initiatives from the Steno Diabetes Center Odense for patients with diabetes.
lupinepublishers-openaccess-journal-diabetes-obesity
The future clinical initiatives await at present to be described in detail. These initiatives will elaborate and extend the already approved initiatives. Multidisciplinary out-patient clinics for patients with diabetes with concomitant rheumatic, cardiac, odontological disease and other chronic diseases are in pipeline. A package for screening of diabetes complications in one day is in pipeline covering type 2 diabetes patients who are followed in the primary health care sector by the primary health care provider, as well as extended follow-up of patients with former gestational diabetes after delivery, and a nurse-based call center for health care professionals and patients followed in the primary health care sector in the Region of Southern Denmark.
Cross-Sectorial Collaboration and Development of Competences and Skills: Hand-in-hand with the above described initiatives a thorough and structured cross-sectorial collaboration between SDCO, partner hospitals, communities and the primary health care providers is currently being developed and implemented. This includes a structured and ongoing training program and theme-based courses for all health care professionals who is taken care of patients with diabetes, in order to further develop and improve competences and skills.
Patient Involvement in the Organization and Clinical Decision-Making at SDCO: Involvement of patients with diabetes and their relatives are considered important at SDCO. It is assumed that involvement in the clinical process can facilitate transformation of knowledge and improve empowerment provided by the health care professionals. Further, the diabetes educators and health care professionals can better adapt and target education, treatment and care to the needs and resources of the individual patient. User involvement at SDCO will focus on both organization (patient board, committees, involvement in new developments etc.), and on individual patient care. Thus, involvement is planned widespread on different relevant areas as: standard patient care, new clinical initiatives, cross-sectorial collaboration, development of competences and skills and clinical research. A patient committee consisting of 15 diabetes patients and relatives of different age, gender, diabetes type, social and educational background has been established. The main purpose with this patient committee is to collaborate with and give advice to the management and health care professionals at the center concerning the future strategy. This in order to ensure that current activities and new clinical initiatives are in agreement with the needs and wishes from patients with diabetes, their relatives and families in the future.

Summary and Conclusions


The overall vision of the new initiatives originating from Steno Diabetes Center Odense and by potential dissemination to the whole Region of Southern Denmark embracing both the primary and secondary health care sector, is to normalize lifetime expectancy and quality of life in people with diabetes. By improving all areas of diabetes management, treatment, care and patient selfcare, it may be possible to avoid or minimize future complications in patients with diabetes irrespective of type of diabetes or concomitant disease. The new and forthcoming clinical and non-clinical initiatives will potentially help to fulfil this goal.


For more Lupine Publishers Open Access Journals Please visit our website:
http://lupinepublishers.us/

To Know More About Open Access Publishers Please Click on Lupine Publishers


Follow on Twitter   :  https://twitter.com/lupine_online

Wednesday, February 19, 2020

Tuesday, February 18, 2020

Sunday, February 2, 2020











For more Lupine Publishers Open access journals please visit our website : 
For more Diabetes open access journal please click here : 

Epidemiology of Osteoporosis in Patients with Type 1 Diabetes Mellitus

Abstract

Background and Objective: The incidence of type 1 diabetes is increasing. Osteoporosis has become an alarming health problem throughout the entire world. The aim of this study were to estimate the epidemiology of osteoporosisamong Saudi patients with T1DM, living in the western province, attending the diabetes centre at King Fahd Armed Forces Hospital, Jeddah, KSA.
Methods: Eligible patients were older than 12 years old, had T1DM . All patients were recruited from the population of the Diabetic Centre at King Fahad Armed Forces Hospital. Eligible patients met with investigators for a complete history and physical examination, to have baseline laboratory assessments including glycosylated haemoglobin (HbA1c). HbA1c was expressed as percentage and measured using the high-performance liquid chromatography. BMD in the current study was measured using The Lunar Achilles (In Sight, GE Healthcare, USA), which is a proven bone ultrasonometer to avoid exposing the children to unnecessarily ionizing radiation. All measurements were converted to Z-scores using a data bank for age-matched speed of sound values supplied by the manufacturer. We excluded patients with a history of fractures of less than 1 year and those with associated bone/joint problems, liver disease or patients on long-term steroid therapy
Main results: 137 patients completed the study. There were 60 (44%) male and 77 (56%) were female with mean age 19.1±4.9. Osteoporosis was found in 53 of cases (38.7%) of patients. There were 23 (43.4%) male and 30 (56.6%) were female giving a female to male ratio 1.3:1. Osteoporosis was found in 53 of cases (38.7%) of patients. Baseline characteristics are shown in Table 1. Patients with osteoporosis were significantly younger, longer diabetes duration and have higher HbA1c than patients without osteoporosis. Osteoporosis was higher in females than male and was seen more in cases with HbA1c > 9.0 as compared to HbA1c groups of < 8.0 and 8-9, (Figures 1 & 2). Cases with longer diabetes duration (≥6years) have nonsignificant more frequent osteoporosis than cases with diabetes duration < 6 years, 34% vs. 66% respectively, p=0.4. There were no significant differences between genders and frequency of osteoporosis in relation to diabetes duration.
Conclusion: Our findings demonstrate lower BMD in young women with type 1 diabetes. Although bone density testing is not routinely performed in young women, these data suggest that screening may be important in young women with type 1 diabetes. In addition, these women should be counseled regarding lifestyle interventions that may improve bone health, including adequate intake of calcium and vitamin D, and exercise.

Introduction

Type 1 diabetes mellitus (T1DM) results from a cellularmediated autoimmune destruction of the β-cells of the pancreas [1]. T1DM accounts for about 10% of all diabetes, affecting approximately 1.4 million people in the U.S, and 10-20 million globally [2]. The prevalence of T1DM was 0.193% in the Saudi males and 0.237% in the Saudi females [3] Osteoporosis has become an alarming health problem throughout the entire world, and approximately 200 million people in the world are threatened by this deleterious disease [4,5]. Osteoporosis is often described as a silent disease because it is typically asymptomatic until a fracture occurs [6]. Along with increased risk of complications including retinopathy, nephropathy, neuropathy, and cardiovascular events, adults with type 1 diabetes have decreased bone mineral density (BMD) compared with control subjects [7,8]. In fact, osteoporosis is the most significant metabolic bone disease in individuals with diabetes [9]. Patients with diabetes are at risk for osteoporosis and its complications, including hip fracture [10]. Recent studies demonstrate that diabetes is associated with alterations in bone health in children and adolescents [6,11-13]. These observations suggest that adverse effects on bone health may occur early after the diabetes diagnosis. This study was undertaken to estimate the epidemiology of osteoporosis among Saudi patients with T1DM, living in the western province, attending the diabetes centre at King Fahd Armed Forces Hospital, Jeddah, KSA.

Methods

Eligible patients were older than 12 years old, had T1DM. All patients were recruited from the population of the Diabetic Centre at King Fahad Armed Forces Hospital. All the patients gave their or their guardian informed consent prior to their inclusion. Eligible patients met with investigators for a complete history and physical examination, to have baseline laboratory assessments including glycosylated hemglobin (HbA1c). HbA1c was expressed as percentage and measured using the high performance liquid chromatography. BMD in the current study was measured using The Lunar Achilles (Insight, GE Healthcare, USA), which is a proven bone ultrasonometer to avoid exposing the children to unnecessarily ionizing radiation. All measurements were converted to Z-scores using a data bank for age-matched speed of sound values supplied by the manufacturer. We excluded patients with a history of fractures of less than 1 year and those with associated bone/joint problems, liver disease or patients on long-term steroid therapy.

Statistical Analysis

Univariate analysis of baseline and follow up demography and clinical laboratory endpoints were accomplished using unpaired t-test where appropriate. Chi square(X2) test were used for categorical data comparison. All statistical analyses were performed using SPSS Version 22.0. All P values were based on two-sided tests. The difference between groups was considered significant when P<0.05.

Results

Baseline characteristics are shown in table 1. 137 patients completed the study. There were 60 (44%) male and 77 (56%) were female with mean age 19.1±4.9 (minimum=12, maximum = 37) years. Osteoporosis was found in 53 of cases (38.7%) of patients. There were 23 (43.4%) male and 30 (56.6%) were female giving a female to male ratio 1.3:1. Patients with osteoporosis were significantly younger, longer diabetes duration and have higher HbA1c than patients without osteoporosis. Osteoporosis was higher in females than male and was seen more in cases with HbA1c > 9.0 as compared to HbA1c groups of < 8.0 and 8-9, (Figures 1 & 2). Cases with longer diabetes duration (≥6years) have nonsignificant more frequent osteoporosis than cases with diabetes duration <6 years, 34% vs. 66% respectively, p=0.4. There were no significant differences between genders and frequency of osteoporosis in relation to diabetes duration (Figure 3).
Figure 1: Percentage of cases of type 1 diabetes mellitus associated with osteoporosis in relation to gender.
lupinepublishers-openaccess-journal-diabetes-obesity
Figure 2: Number of cases of type 1 diabetes mellitus associated with osteoporosis in relation to HbA1c groups.
lupinepublishers-openaccess-journal-diabetes-obesity
Figure 3: Number of cases with type 1 diabetes mellitus associated with osteoporosis in relation to diabetes duration (years).
lupinepublishers-openaccess-journal-diabetes-obesity

Discussion

In agreement with many studies, the present study has confirmed that osteoporosis is associated with T1DM.
[14-16] However, it was unclear until recently whether this translated into increased fracture rates. A number of studies have shown that poor glycemic control in patients with T1DM is associated with osteopenia and osteoporosis [17,18]. Poor glycemic control for long period of time can result into microvascular complications and can aggravate the loss of bone density by various mechanisms. Nephropathy can predispose patients with diabetes to hypercalciuria and can alter the vitamin D metabolism causing vitamin D deficiency [19,20]. Hyperglycemia may lead to an increased loss of calcium in the urine, which can in turn cause a negative calcium balance [21]. Furthermore, use of loop diuretics in patients with diabetic nephropathy is associated with low bone mineral density (BMD) as these drugs cause the renal excretion of calcium [22]. Insulin-like growth factors and other cytokines may influence diabetic bone metabolism [20]. The decrease bone formation and inadequate accrual peak bone mass in children with prepubertal onset T1DM has been proposed as a major contributing factor for low bone strength and osteoporosis in later life [23]. Men with T1DM tend to be particularly prone to osteopenia or osteoporosis compared to women of similar ages [15,24,25] Estrogen adequacy and/or use of estrogen based oral contraceptive pills might be the reason for higher bone mass in women compared to men [25-26]. Furthermore, hypogonadism is quite common in men with T1DM and that may contribute to osteoporosis in males [27,28]. Another factor which may influence the BMD is body mass index (BMI). Studies have shown that lower BMI is associated with higher incidence of osteoporosis. The adipose tissue, apart from providing mechanical loading, also increases BMD through the activity of adipocytokines. Patients with TIDM also have a negative calcium balance as a result of hypercalciuria during periods of hyperglycemia, functional hypoparathyroidism, vitamin D deficiency and alterations in vitamin D metabolism [29-31]. In concordance with our results, duration of diabetes seems to play a key role given the lower BMD found among patients who have had diabetes for >5 years. In the Iowa Women’s Health Study, women with type 1 diabetes were 12.25 times more likely to report having had a fracture compared to women without diabetes [10]. A low BMI as shown in our study is associated the increased possibility of osteoporosis [32]. Overweight and obesity are believed to be protective factors of BMD [33,34]. Obesity is strongly associated with higher BMD probably through mechanical loading and hormonal factors including insulin, estragon, and leptin [35] In conclusion, our findings demonstrate high frequency of osteoporosis in young women with type 1 diabetes. Although bone density testing is not routinely performed in young women, these data suggest that screening may be important in young women with type 1 diabetes. In addition, these women should be counseled regarding lifestyle interventions that may improve bone health, including adequate intake of calcium and vitamin D, and exercise Table 1.
Table 1: Characteristics of patients with type 1 diabetes mellitus stratified by presence of Osteoporosis.
lupinepublishers-openaccess-journal-diabetes-obesity

Acknowledgment


We are grateful to the staffs from the diabetic centre at King Fahad Armed Forces Hospital for his valuable contributions in data collection. The authors have no conflict of interest to disclose

For more Lupine Publishers Open access journals please visit our website : 
For more Diabetes open access journal please click here : 

Lupine Publishers| Semaglutide versus liraglutide for treatment of obesity

  Lupine Publishers| Journal of Diabetes and Obesity Abstract Background: Once weekly (OW) semaglutide is a glucagon-like peptide...